Bravida Medical spotlights ISHLT 2026 clinical presentations

Bravida Medical highlighted poster and oral presentations featured at the 2026 International Society for Heart and Lung Transplantation meeting in Geneva, recognizing new work on LVAD and ECMO care. The company says the studies add to clinical evidence on infection prevention and best practices for critically ill patients.

Why it matters: - The presentations add to the evidence base for LVAD and ECMO care, two high-risk therapies used for critically ill patients. - The work focused on infection prevention and dressing care, which can affect outcomes for patients with advanced circulatory support. - Bravida Medical is positioning the research as part of broader efforts to support clinically supported solutions in critical care.

What happened: - Bravida Medical highlighted poster presentations and an oral presentation featured at the 2026 Annual Meeting of the International Society for Heart and Lung Transplantation in Geneva. - The featured work came from clinicians and researchers at Northwestern Memorial Hospital, Stanford Health Care and Stanford University School of Medicine, the Medical University of Vienna, and University Hospitals Cleveland Medical Center. - Gina Gilbert, BSN, RN, chief clinical officer at Bravida Medical, said the presentations reflect multidisciplinary collaboration and rigorous clinical study.

The details: - Rheanna Maxey, BSN, RN, CCRN, presented on a standardized dressing kit containing a silver-plated antimicrobial agent in adult ECMO patients. - Hannah Miller, BSN, RN-BC, presented on LVAD driveline dressing care from the patient’s perspective. - Thomas Schlöglhofer presented on the efficacy of antimicrobial silver-coated dressings and usual care in preventing LVAD driveline infections. - Christine Swanson, MSN, AGACNP-BC, presented on whether silver-based dressing use reduces infection rates after left ventricular assist device therapy. - The presentations reflected collaboration among frontline clinicians, researchers, and healthcare organizations focused on improving outcomes for critically ill patients. - Bravida Medical said the posters and presentations contribute to the growing body of clinical evidence supporting best practices in advanced circulatory support and critical care management. - The company thanked the International Consortium of Circulatory Assist Clinicians and the International Society for Heart and Lung Transplantation membership for their work in education, research, and interdisciplinary collaboration. - Bravida Medical provided a clinical evidence page for additional resources. - Bravida Medical also pointed readers to product and safety information.

Between the lines: - The announcement is as much about validating Bravida Medical's clinical positioning as it is about the conference itself. - The focus on silver-based and antimicrobial dressings signals continued interest in reducing device-related infections in LVAD and ECMO care. - The company's messaging links conference visibility with evidence generation and clinician partnerships.

What's next: - Bravida Medical is likely to keep pointing clinicians and customers to its clinical evidence and safety resources as supporting material for product adoption and education. - The studies highlighted at ISHLT 2026 may feed future discussion on best practices for dressing protocols in advanced circulatory support. - The company continues to frame its work around partnerships with clinicians and healthcare organizations worldwide.

The bottom line: - Bravida Medical used ISHLT 2026 to showcase clinical research that reinforces its focus on evidence-based care for LVAD and ECMO patients.